FDA approves AMO procedure

AMO has received Food and Drug Administration approval for the Advanced CustomVue Monovision procedure, for wavefront-guided laser vision correction of low to moderately myopic presbyopic patients with and without astigmatism.

The procedure is individualised and combines the WaveScan WaveFront system with AMO's Iris Registration technology to custom correct myopia in the dominant eye and partially correct it in the other eye, with reduced dependency on reading glasses and contact lenses.

AMO chairman Jim Mazzo described the approval as an industry first. 'The Advanced CustomVue Monovision procedure is the only FDA-approved wavefront-guided Lasik treatment for the correction of both near and distance vision of presbyopic patients,' he said.